

Factsheet **Q4 2020/21**

	Q4 19/20	Q4 20/21	YTD 19/20	YTD 20/21			
Income statement, continuing operations (EUR m)							
Revenue	254.3	293.3	970.0	1,077.4			
Gross profit	156.7	169.4	584.0	613.4			
EBITDA b.s.i.	121.0	111.8	400.6	399.3			
EBIT b.s.i.	97.7	84.2	326.9	298.1			
EBIT	88.9	84.1	313.0	276.2			
Net financial items	(4.3)	(6.4)	(13.5)	(22.5)			
Group profit for the period	66.2	69.2	245.0	845.2			
Cash flow and investments, continuing operations (EUR m)							
Operating cash flow	123.9	135.0	329.8	328.0			
Operational investing cash flow	(51.3)	(58.6)	(118.8)	(153.5)			
M&A	(537.8)	-	(657.2)	(318.2)			
Free cash flow b.s.i.a.d.	81.4	76.5	224.9	196.4			
Balance sheet, Group (EUR m)							
Total assets			2,853.6	3,114.2			
Invested capital			2,487.6	2,793.1			
Net working capital			208.1	190.1			
Equity			893.0	1,626.1			
Net interest-bearing debt			1,345.0	898.2			
Key ratios (%)							
Continuing operations							
Gross margin	61.6%	57.8%	60.2%	56.9%			
EBITDA margin b.s.i.	47.6%	38.1%	41.3%	37.1%			
EBIT margin b.s.i	38.4%	28.8%	33.7%	27.7%			
Underlying EBIT b.s.i. margin ¹	38.2%	32.6%	33.6%	31.4%			
R&D	6.7%	8.6%	8.0%	8.5%			
Сарех	20.2%	20.0%	12.2%	14.5%			
ROIC excl. goodwill	38.1%	25.8%	33.6%	24.8%			
ROIC	18.8%	12.0%	16.5%	11.6%			
Net debt to EBITDA b.s.i.			3.1x	2.3x			



Revenue split by region, YTD



	Q4 19/20	Q4 20/21	YTD 19/20	YTD 20/21		
Growth drivers, continuing operations (%)						
Organic growth	9%	6%	6%	7%		
Volume/mix	5%	4%	4%	3%		
Price	4%	2%	2%	4%		
Currencies	-6%	-3%	-3%	-7%		
M&A	<1%	12%	0%	11%		
EUR growth	3%	15%	3%	11%		
Organic growth by region, continuing operations (%)						
EMEA	3%	11%	3%	6%		
NA	1%	4%	4%	6%		
LATAM	47%	15%	24%	26%		
APAC	10%	-10%	6%	-3%		
Food Cultures & Enzymes (I						
Revenue	173.3	185.9	693.1	700.5		
Organic growth	5%	10%	5%	8%		
Volume/mix	0%	8%	3%	3%		
Currencies	-8%	-3%	-3%	-7%		
M&A	-	-	-	-		
EUR growth	-3%	7%	2%	1%		
EBITDA b.s.i.	79.1	76.3	285.2	277.7		
EBITDA margin b.s.i.	45.6%	41.0%	41.1%	39.6%		
EBIT b.s.i.	66.7	61.4	237.8	224.0		
EBIT margin b.s.i.	38.4%	33.0%	34.3%	32.0%		
ROIC excl. goodwill			41.1%	35.8%		
Health & Nutrition (EUR m / %)						
Revenue	81.0	107.4	276.9	376.9		
Organic growth	18%	-4%	9%	5%		
Volume/mix	19%	-7%	10%	3%		
Currencies	-6%	-2%	-1%	-6%		
M&A	>2%	39%	1%	37%		
EUR growth	15%	33%	9%	36%		
EBITDA b.s.i.	41.9	35.9	115.4	122.0		
EBITDA margin b.s.i.	51.7%	33.4%	41.7%	32.4%		
EBIT b.s.i.	31.0	23.2	89.1	74.5		
EBIT margin b.s.i.	38.3%	21.6%	32.2%	19.8%		
Underlying EBIT margin b.s.i. ¹	37.5%	32.1%	31.9%	30.0%		
ROIC excl. goodwill			22.6%	13.0%		

¹See Q4 2020/21 company announcement, p. 22, for reconciliation of underlying margins.

CHR HANSEN Improving food & health